Dasatinib, marketed as Sprycel by Bristol Myers Squibb (BMS), has several patents protecting its composition and method of use [1]. The earliest patent related to dasatinib's composition of matter was filed in 2000 by the National Institutes of Health and was later assigned to Bristol Myers Squibb [2].
When does dasatinib patent protection expire?
The patent landscape for dasatinib is complex, with multiple patents covering different aspects of the drug. DrugPatentWatch.com provides detailed information on these patents and their expiration dates [1]. While the initial composition of matter patent was filed in 2000, subsequent patents related to manufacturing, formulation, and methods of treatment extend the overall patent protection period. Generic drug manufacturers often challenge these patents to try and bring their versions to market earlier [3].
What are the key patents for dasatinib?
Key patents for dasatinib include those covering its chemical structure, methods for its synthesis, and specific therapeutic uses, such as in certain types of leukemia [2]. The precise expiration dates can vary for each patent, and some may be subject to litigation or extensions, which can affect market exclusivity [1].
Can generic dasatinib enter the market before patent expiry?
The entry of generic dasatinib depends on the outcome of patent litigation. Generic companies may attempt to invalidate existing patents or argue that their product does not infringe on them. If these challenges are successful, generic versions could become available before the expiration of all relevant patents [3]. However, Bristol Myers Squibb actively defends its intellectual property [1].
How does dasatinib compare to other leukemia treatments?
Dasatinib is a tyrosine kinase inhibitor (TKI) used primarily for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [4]. It targets specific proteins that drive cancer cell growth [5]. Other TKIs, such as imatinib (Gleevec), nilotinib (Tasigna), and bosutinib (Bosulif), are also used for these conditions, each with its own efficacy and side effect profile [6].
What are the potential risks or side effects of dasatinib?
Common side effects associated with dasatinib include myelosuppression (low blood cell counts), fluid retention, diarrhea, rash, nausea, and fatigue [4]. More serious side effects can include bleeding events, cardiovascular issues, and pulmonary arterial hypertension [7]. Patients and healthcare providers monitor for these effects closely [4].
Sources:
1. https://drugpatentwatch.com/
2. US Patent 7,585,993
3. Various legal filings and analyses of pharmaceutical patent litigation.
4. Sprycel (dasatinib) prescribing information.
5. BMS.com, Dasatinib product information.
6. National Comprehensive Cancer Network (NCCN) Guidelines.
7. FDA drug safety communications.